38 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-ß-lactamases and arginases.
The University of Queensland
Synthesis of quaternarya-amino acid-based arginase inhibitors via the Ugi reaction.
Institutes For Pharmaceutical Discovery
2-Substituted-2-amino-6-boronohexanoic acids as arginase inhibitors.
Institutes For Pharmaceutical Discovery
Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury.
Institutes For Pharmaceutical Discovery
N(delta)-Methylated L-arginine derivatives and their effects on the nitric oxide generating system.
Christian-Albrechts-University of Kiel
Synthesis of a new trifluoromethylketone analogue of l-arginine and contrasting inhibitory activity against human arginase I and histone deacetylase 8.
Drexel University
Binding ofa,a-disubstituted amino acids to arginase suggests new avenues for inhibitor design.
Drexel University
2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.
University of Pennsylvania
Synthesis and evaluation of piceatannol derivatives as novel arginase inhibitors with radical scavenging activity and their potential for collagen reduction in dermal fibroblasts.
Universite de Franche-Comte
Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective.
University of Turin
Discovery of (2R,4R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer.
AstraZeneca
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
University of Cambridge
Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion.
Molecure
A colorimetric assay adapted to fragment screening revealing aurones and chalcones as new arginase inhibitors.
Universite de Franche-Comte
Chemical similarities and differences among inhibitors of nitric oxide synthase, arginase and dimethylarginine dimethylaminohydrolase-1: Implications for the design of novel enzyme inhibitors modulating the nitric oxide pathway.
Flinders University
Recent advances in small molecule based cancer immunotherapy.
Southern Medical University
Discovery of non-boronic acid Arginase 1 inhibitors through virtual screening and biophysical methods.
Merck
If small molecules immunotherapy comes, can the prime be far behind?
Zhejiang University
Targeting Metalloenzymes by Boron-Containing Metal-Binding Pharmacophores.
Sichuan University
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.
Merck
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology.
Quantitative Biosciences
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.
Univ. Bourgogne Franche-Comt�
Novel Arginase Inhibitors for Treating Cancer and Respiratory Inflammatory Diseases.
Smith, Gambrell & Russell
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer Immunotherapy.
Merck
1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
University of Louvain
Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 Inhibitors.
Oncoarendi Therapeutics
Purine derivatives and the use thereof as medicament
Boehringer Ingelheim International